Trial ID or NCT#

NCT03295396

Status

recruiting iconRECRUITING

Purpose

The primary objective of this phase II trial is to determine the efficacy and safety of ONC201, an oral small molecule imipridone DRD2 antagonist, in adult subjects with recurrent high-grade glioma. This study will test the research hypothesis that histone H3 K27M mutation sensitizes to oral administration of ONC201 in gliomas.

Official Title

A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Reena Thomas, MD PhD
Reena Thomas, MD PhD
Neuro-oncologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Chirag Patel, MD, PhD
Chirag Patel, MD, PhD
Neuro-oncologist
Clinical Assistant Professor, Neurology & Neurological Sciences Clinical Assistant Professor, Radiology - Rad/Molecular Imaging Program at Stanford

Contact us to find out if this trial is right for you.

CONTACT

Hari Priya Yarraballa
(650) 724-9363